{"created":"2022-05-11T01:43:02.170252+00:00","id":2002703,"links":{},"metadata":{"_buckets":{"deposit":"164a5fdf-8f4f-4011-b748-af3afe30c472"},"_deposit":{"created_by":17,"id":"2002703","owner":"17","owners":[17],"pid":{"revision_id":0,"type":"depid","value":"2002703"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:02002703","sets":["499:500:501"]},"author_link":[],"control_number":"2002703","item_1615768549627":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_1629683748249":{"attribute_name":"日付","attribute_value_mlt":[{"subitem_date_issued_datetime":"2023-04-01","subitem_date_issued_type":"Available"}]},"item_9_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2022-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"1716","bibliographicPageStart":"1709","bibliographicVolumeNumber":"61","bibliographic_titles":[{"bibliographic_title":"Rheumatology","bibliographic_titleLang":"en"}]}]},"item_9_description_4":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Objective: Anti-NOR90 antibodies are usually found in patients with SSc; however, their clinical relevance remains obscure. We developed an ELISA for measuring them to investigate the clinical features of patients with anti-NOR90 antibodies. Methods: Serum samples from 1252 patients with various conditions from Nagoya University Hospital and 244 patients with idiopathic interstitial pneumonia (IIP) from Tosei General Hospital were included. Anti-NOR90 antibodies were assayed by an ELISA using the recombinant protein produced by in vitro transcription/translation. Results: Five (0.4%) patients in the Nagoya University Hospital cohort had anti-NOR90 antibodies. One patient with diffuse cutaneous SSc, three with limited cutaneous SSc, and one with Raynaud’s disease were positive for anti-NOR90 antibodies. Anti-NOR90 antibodies were found more frequently in patients with systemic scleroderma-spectrum disorders (SSDs) than without SSDs (5/316 vs 0/936, P <0.00101) and were found more frequently in patients with SSc than without SSc (4/249 vs 0/528, P <0.0104) in the systemic autoimmune rheumatic diseases cohort. Three of the four anti-NOR90-positive SSc patients had interstitial lung disease (ILD), and two of those four had cancer. Three (1.2%) patients in the Tosei General Hospital cohort had anti-NOR90 antibodies. All three of the anti-NOR90-positive IIP patients had gastrointestinal tract involvement, and two of those three had cancer or skin lesions observed in SSc. Conclusions: Although anti-NOR90 antibodies are rarely found in clinics, our ELISA is useful for their detection. Further studies are needed to confirm the association of anti-NOR90 antibodies with ILD and cancer in SSc and IIP patients.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_9_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Oxford University Press","subitem_publisher_language":"en"}]},"item_9_relation_43":{"attribute_name":"関連情報","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1093/rheumatology/keab575","subitem_relation_type_select":"DOI"}}]},"item_9_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This is a pre-copyedited, author-produced version of an article accepted for publication in [Rheumatology] following peer review. The version of record [Yuta Yamashita, Yasuhiko Yamano, Yoshinao Muro, Mariko Ogawa-Momohara, Takuya Takeichi, Yasuhiro Kondoh, Masashi Akiyama, Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia, Rheumatology, Volume 61, Issue 4, April 2022, Pages 1709–1716, https://doi.org/10.1093/rheumatology/keab575] is available online at: https://doi.org/10.1093/rheumatology/keab575.","subitem_rights_language":"en"}]},"item_9_source_id_7":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"1462-0324","subitem_source_identifier_type":"PISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yamashita, Yuta","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamano, Yasuhiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Muro, Yoshinao","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ogawa-Momohara, Mariko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takeichi, Takuya","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kondoh, Yasuhiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Akiyama, Masashi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2023-04-01"}],"displaytype":"detail","filename":"RHE-21-1210_R1_Proof_hi.pdf","filesize":[{"value":"908 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/2002703/files/RHE-21-1210_R1_Proof_hi.pdf"},"version_id":"0c0eb4b6-c218-4f94-8890-7e7d9eeb4dcc"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"anti-NOR90 antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"anti-nucleolar antibody","subitem_subject_scheme":"Other"},{"subitem_subject":"cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"idiopathic interstitial pneumonia","subitem_subject_scheme":"Other"},{"subitem_subject":"interstitial lung disease","subitem_subject_scheme":"Other"},{"subitem_subject":"systemic autoimmune rheumatic disease","subitem_subject_scheme":"Other"},{"subitem_subject":"systemic sclerosis","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"17","path":["501"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-05-11"},"publish_date":"2022-05-11","publish_status":"0","recid":"2002703","relation_version_is_last":true,"title":["Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia"],"weko_creator_id":"17","weko_shared_id":-1},"updated":"2023-04-05T00:58:20.543178+00:00"}